Skip to content

SKB264 tumor-growth inhibition

A reduced tumor-growth model representing the balance between untreated tumor expansion and SKB264-associated tumor-cell killing.

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132 ↗

Frontiers in Oncology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How fast does an untreated tumor grow over 30 days?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Starting example

Default model behavior

Default model behavior

How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth? Explore this biological starting configuration through Tumor volume, Net tumor growth rate.

0–30 day

Scenario details

Default model behavior

How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth? Explore this biological starting configuration through Tumor volume, Net tumor growth rate.

Readouts

Tumor volume · millimeter**3
Tumor volume over the selected simulation window.
Net tumor growth rate · Unit unavailable
Net tumor growth rate over the selected simulation window.

Study purpose

  • How does the modeled ADC killing rate change tumor-volume dynamics relative to intrinsic growth?

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Model parameter

Tumor growth rate governing growth in the modeled biological process.

1/day

Suggested: 0.02–0.06. You can explore beyond this range.

0.04 → —

Tumor kill rate governing loss, degradation, or removal in the modeled biological process.

1/day

Suggested: 0–1. You can explore beyond this range.

0 → —
Simulation time
day
day
30 → 168

Time between reported samples.

day
0.25 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

An intrinsic tumor-growth rate and a scenario-defined tumor-kill coefficient oppose one another to set net growth, which changes the single tumor-volume state.

How do intrinsic growth and a scenario-defined kill coefficient shape tumor volume?An intrinsic tumor-growth rate and a scenario-defined tumor-kill coefficient oppose one another to set net growth, which changes the single tumor-volume state.BIOLOGY OVERVIEWHow do intrinsic growth and a scenario-defined kill coefficient shape tumorvolume?Intrinsic growth rate: Positive tumor-growth coefficientIntrinsic growthratePositive tumor-growthcoefficientKill coefficient: Scenario-defined negative driveKill coefficientScenario-defined negativedriveNet growth balance: Growth minus kill coefficientNet growth balanceGrowth minus kill coefficientTumor volume: Single dynamic tumor stateTumor volumeSingle dynamic tumor statePRIMARY READOUTSTumor volumeTumor volumeNet tumor-growth rateNet tumor-growth rate

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: ADC exposure, TROP2 binding, payload release, dose response, and a separate cell-death compartment are not represented; the public default kill coefficient is zero.

Modeled relationships (3)
  • Intrinsic growth rate → Net growth balance: positive drive (modulation)
  • Kill coefficient → Net growth balance: negative drive (modulation)
  • Net growth balance → Tumor volume: changes V (modulation)

Modeled relationships: Intrinsic growth rate to Net growth balance: positive drive (modulation); Kill coefficient to Net growth balance: negative drive (modulation); Net growth balance to Tumor volume: changes V (modulation).

Primary readouts: Tumor volume; Net tumor-growth rate.

Model details

2 parameters · 1 states · 1 equations · 4 derived outputs

Classification & API access
Therapeutic
SKB264 (sacituzumab tirumotecan), anti-TROP2 humanized mAb shared with IMMU-132
Modality
Antibody–drug conjugate (ADC)
Target
TACSTD2, TROP2, EGP1
Disease / scope
TROP2-positive preclinical tumor models
ParameterDefaultUnitDescription
Tumor growth ratetumor_growth_rate_day0.041/dayTumor growth rate governing growth in the modeled biological process.
Tumor kill ratetumor_kill_rate_day01/dayTumor kill rate governing loss, degradation, or removal in the modeled biological process.

Related models

Enfortumab vedotin and MMAE concentration-input referenceCharged trastuzumab ADC plasma dispositionInotuzumab ozogamicin conditional pharmacokineticsATC161 exposure and alpha-synuclein aggregate degradation

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics